Fatty liver. ?Fatty (change of) liver, not elsewhere classified
Conditions
Interventions
Intervention 1: Cynarol,200 mg oral tablet, 3 times a day for 8 weeks. Intervention 2: placebo,200mg oral tablet,3 times a day for 8 weeks.
Treatment - Drugs
Placebo
Cynarol,200 mg oral tablet, 3 times a day for 8 weeks
placebo,200mg oral tablet,3 times a day for 8 weeks
Sponsors
Vice chancellor for research of Baqiyatallah University of Medical Science
Eligibility
Sex/Gender
All
Age
18 Years to 139 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: patient has Fatty Liver; The history of allergic reaction to the drug combination is not relevant; Over 18 years old; The patient has informed consent to participate in the study; Exclusion criteria: The patient who stops the medication more than 1 week; The patient with the history of biliary disease; The patient with Fatty Liver, who also has Hyperlipidemia and receives statins; Patient with Fatty Liver, who also has another liver disease; Pregnancy and lactation; The patient who expresses uncontrolled adverse effects by this drug; Alcohol consumption and any addictive drugs..
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The accumulation of liver fat. Timepoint: Before the intervention, 8 weeks later at the end of the intervention. Method of measurement: Color Doppler Ultrasonography. | — |
Secondary
| Measure | Time frame |
|---|---|
| LDL. Timepoint: Before the intervention, 8 weeks later at the end of the intervention. Method of measurement: Blood test.;HDL. Timepoint: Before the intervention, 8 weeks later at the end of the intervention. Method of measurement: Blood test.;Portal vein diameter. Timepoint: Before the intervention, 8 weeks later at the end of the intervention. Method of measurement: Color Doppler Ultrasonography.;TG. Timepoint: Before the intervention, 8 weeks later at the end of the intervention. Method of measurement: Blood test.;Total Cholesterol. Timepoint: Before the intervention, 8 weeks later at the end of the intervention. Method of measurement: Blood test.;FBS. Timepoint: Before the intervention, 8 weeks later at the end of the intervention. Method of measurement: Blood test.;HbA1C. Timepoint: Before the intervention, 8 weeks later at the end of the intervention. Method of measurement: Blood test.;Uric Acid. Timepoint: Before the intervention, 8weeks later at the end of the intervention. Method of measurement: Blood test.;Hepatic blood flow velocity. Timepoint: before the intervention8weeks later at the end of intervention. Method of measurement: Color Doppler Ultrasonography.;ALT. Timepoint: before the intervention,8 weeks later at the end of intervention. Method of measurement: Blood test.;AST. Timepoint: before the intervention,8 weeks later at the end of intervention. Method of measurement: Blood test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactKianpour Parisa
Islamic Azad University of Pharmaceutical Science
Outcome results
None listed